Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 3c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.38), $0.03 better than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• NVE Corporation names new CEO and expands board to seven members